These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease. Naoi M; Maruyama W Expert Rev Neurother; 2009 Aug; 9(8):1233-50. PubMed ID: 19673610 [TBL] [Abstract][Full Text] [Related]
10. Can an adjuvant treatment or a pharmacologic prevention be common to several diseases? The case of those associated to neuromediator defects. Mathé G Biomed Pharmacother; 1995; 49(4):161-7. PubMed ID: 7669935 [TBL] [Abstract][Full Text] [Related]
11. Neuroprotective therapy in Parkinson disease. Chen S; Le W Am J Ther; 2006; 13(5):445-57. PubMed ID: 16988541 [TBL] [Abstract][Full Text] [Related]
12. Neuroprotection for Parkinson's disease: prospects and promises. Olanow CW; Schapira AH; Agid Y Ann Neurol; 2003; 53 Suppl 3():S1-2. PubMed ID: 12666093 [No Abstract] [Full Text] [Related]
13. Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. Chen JJ; Swope DM J Clin Pharmacol; 2005 Aug; 45(8):878-94. PubMed ID: 16027398 [TBL] [Abstract][Full Text] [Related]
14. Preclinical versus clinical neuroprotection. Grünblatt E; Schlösser R; Gerlach M; Riederer P Adv Neurol; 2003; 91():309-28. PubMed ID: 12442689 [No Abstract] [Full Text] [Related]
15. Reexamination of the TEMPO Study. Shults CW Arch Neurol; 2005 Aug; 62(8):1320; author reply 1321. PubMed ID: 16087778 [No Abstract] [Full Text] [Related]
16. [The early therapy challenge]. Reichmann H Krankenpfl J; 2005; 43(7-10):240. PubMed ID: 16515310 [No Abstract] [Full Text] [Related]
17. Clinical trial of a new type promptly acting psychoenergetic agent (phenyl-isopropyl-methylpropinyl-HCl, "E-250"). Varga E; Tringer L Acta Med Acad Sci Hung; 1967; 23(3):289-95. PubMed ID: 6056555 [No Abstract] [Full Text] [Related]
18. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Chen JJ; Swope DM; Dashtipour K Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186 [TBL] [Abstract][Full Text] [Related]
19. Caffeine as a neuroprotective adenosine receptor antagonist. Dall'Igna OP; Souza DO; Lara DR Ann Pharmacother; 2004 Apr; 38(4):717-8. PubMed ID: 14982979 [No Abstract] [Full Text] [Related]